从 FDA 批准药物中鉴定抗 SARS-CoV-2 的抗病毒候选药物。
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
机构信息
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea.
Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea.
出版信息
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00819-20.
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (ICs), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.
药物重定位是立即应对 COVID-19 全球挑战的唯一可行选择。我们针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）筛选了一组 48 种美国食品和药物管理局批准的药物，这些药物是通过 SARS-CoV 检测预先选择的。我们鉴定出 24 种针对 SARS-CoV-2 感染的有潜力的抗病毒候选药物。一些候选药物显示出非常低的 50%抑制浓度（ICs），特别是两种美国食品和药物管理局批准的药物——尼氯硝唑和环索奈德——在某些方面表现突出。
Zotero 插件